Premium
Comparative ProteinChip Array Profiling of Human, Non‐human Primate, Pig, Dog, Rabbit, Rat, and Mice Plasma Using Surface Enhanced Laser Desorption Ionization (SELDI) Method
Author(s) -
Florian Michelle,
Cera L,
Duff R,
Maddineni J,
Hoppensteadt D,
Valero A,
Beusing R,
Fareed J,
Kennedy R
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.a1104-c
Subject(s) - biomarker , proteomics , biomarker discovery , surface enhanced laser desorption/ionization , biology , chemistry , microbiology and biotechnology , mass spectrometry , biochemistry , gene , chromatography , electrospray ionization , protein mass spectrometry
With the advent of genomics and proteomics, pathophysiologic alterations of the regulatory processes and cellular expression products can be readily profiled. Since a new approach using surface enhanced laser desorption/ionization (SELDI) has become available, it is possible to obtain a more comprehensive molecular profile of plasma from different species, especially in the molecular weight range of <25 kDa. In order to demonstrate species dependent variation in protein/peptide distribution profile in the range of 150–150,000 Da, plasma samples from human, non‐human primate, pig, dog, rabbit, rat and mouse were analyzed using anionic biomarker chips. Although the overall protein distribution patterns were similar, there were several specific biomarkers that were unique to a given species. Human and primates showed certain similarities in the protein biomarker profiles. Of major interest were the differences in the region below 20 kDa. Marked differences in the biomarker distribution profile were noted among all species. Each species exhibited a characteristic biomarker profile in the 5–10 kDa range. It is likely that in pathophysiologic condition, the distribution of the biomarkers may further change. Because of this molecular heterogeneity of the biomarker peak in the resting states, the proteomic profiling of different diseases in animal models should be carefully evaluated.